Skip to main content

Drug Interactions between Actidose Plus Sorbitol and leflunomide

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

charcoal leflunomide

Applies to: Actidose Plus Sorbitol (charcoal / sorbitol) and leflunomide

GENERALLY AVOID: A significant decrease in M1, the active metabolite of leflunomide, has resulted when cholestyramine or activated charcoal is administered to patients receiving leflunomide. Administration of cholestyramine 8 grams 3 times a day has resulted in a 40% decrease in plasma levels of M1 in a 24 hour period.

MANAGEMENT: Coadministration of these drugs is not recommended.

References (1)
  1. (2001) "Product Information. Arava (leflunomide)." Hoechst Marion Roussel

Drug and food interactions

Moderate

leflunomide food

Applies to: leflunomide

GENERALLY AVOID: The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury. Leflunomide has been associated with hepatotoxicity, including elevated liver transaminases, hepatitis, jaundice/cholestasis, hepatic failure, and acute hepatic necrosis,

MANAGEMENT: Patients should be advised to avoid excessive alcohol use during leflunomide treatment.

References (3)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
  3. Cerner Multum, Inc. "Australian Product Information."

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer